Roche files IND for antibody developed in collaboration with Genmab

By E. Janene Geiss

Philadelphia, Dec. 13 - Genmab AS announced Tuesday that its partner Roche has filed an Investigational New Drug Application with the Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.

This is the ninth milestone Genmab has achieved under the agreement, company officials said in a news release.

Genmab will receive an undisclosed milestone payment from Roche. The payment will not influence Genmab's financial guidance for 2005, officials said.

Under the agreement, Genmab said it uses its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche.

In certain circumstances, Genmab said it may obtain rights to develop products based on disease targets identified by Roche.

If all goals are reached, the value of the collaboration to Genmab could be $100 million plus royalties, officials said.

Roche has selected four Genmab antibodies as clinical candidates, and this is the first of the four to enter the clinic.

"This move to clinical development is a testament to Genmab's antibody discovery skills as well as Roche's skill in identifying valid disease targets," said Lisa N. Drakeman, chief executive officer of Genmab, in the release.

Genmab is a Copenhagen, Denmark, biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.